Latest Breaking News On - Savolitinib plus osimertinib - Page 1 : comparemela.com

Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.

T ai peiNational taiwan universityNational taiwan university hospitalJames chih hsin yangNational taiwan university cancer centreSavolitinib plus osimertinibPatients with nsclcMet amplification cutoffs